Safe and cost-effective treatments for respiratory diseases are facing a growing demand. The demonstration of bioequivalence within locally acting drugs, such as orally inhaled products, could prove particularly challenging.
This article was taken from pharmaceutical Manufacturing and Packing Sourcer February 2018. © Samedan Ltd
